Sep 28, 2023 17:05 JST

Source: Eisai

Eisai Launches New "Innovation" Page on Corporate Website

Eisai Co., Ltd. announced today that it has launched a new “Innovation” page on its corporate website. The "Innovation" page is comprised of four sections: "Research & Development (R&D)," "Ecosystem," "Open Innovation," and "Corporate Venture Capital," which are the core of Eisai’s innovation creation. Each part introduces information such as Eisai’s strengths, originality, and the status of specific initiatives.

"Innovation" top page www.eisai.com/innovation/index.html

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept, (also known as our human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities.

On the newly established "Innovation" page, Eisai has enhanced information on policies, characteristics, and examples of initiatives for innovation creation aimed at realizing it’s corporate concept. The “R&D” section contains new contents, such as an overview of the Deep Human Biology Learning (DHBL) drug discovery and development system, which was established last year, track records of Eisai’s long-term commitment to dementia, oncology and tropical diseases, and the current status of digital technology application in R&D settings. In addition, the "Ecosystem" section explains Eisai’s policy of evolving into an hhceco (hhc concept + ecosystem) company to empower people to “realize their fullest lives” how they would like, from the time that they are in good health up to their final moments, and the dementia hhceco model on which Eisai is focusing. Moreover, the “Open Innovation” and “Corporate Venture Capital” sections introduce their respective business policies and achievements, and an inquiry page for new partnering opportunities has been established.

Eisai will continue to disclose information in a proactive and easy-to-understand manner through our corporate website and communicate with all of our stakeholders to help them understand our corporate concept and business activities.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
November 30 2023 15:25 JST
 
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting
November 22 2023 08:28 JST
 
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
November 20 2023 16:05 JST
 
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023
October 25 2023 19:43 JST
 
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference
October 16 2023 13:07 JST
 
Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023
October 11 2023 12:07 JST
 
Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
October 04 2023 18:08 JST
 
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance"
September 28 2023 13:49 JST
 
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan
September 25 2023 14:17 JST
 
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21
September 21 2023 11:26 JST
 
More Press release >>

Latest Press Release


More Latest Release >>